HC Wainwright Reiterates “Buy” Rating for UroGen Pharma (NASDAQ:URGN)

UroGen Pharma (NASDAQ:URGN)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a research note issued on Thursday, MarketBeat Ratings reports. They currently have a $54.00 target price on the stock. HC Wainwright’s price objective would indicate a potential upside of 293.30% from the stock’s current price.

Separately, Oppenheimer reduced their price target on shares of UroGen Pharma from $35.00 to $34.00 and set an “outperform” rating on the stock in a research report on Friday, March 15th.

UroGen Pharma Stock Down 3.7 %

NASDAQ URGN opened at $13.73 on Thursday. The stock has a market cap of $322.02 million, a P/E ratio of -3.68 and a beta of 1.07. The company’s 50-day simple moving average is $16.19 and its 200 day simple moving average is $14.59. UroGen Pharma has a twelve month low of $8.69 and a twelve month high of $24.13.

UroGen Pharma (NASDAQ:URGN) last posted its earnings results on Thursday, March 14th. The company reported ($0.72) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.05). The company had revenue of $23.53 million for the quarter, compared to analyst estimates of $22.30 million. Research analysts anticipate that UroGen Pharma will post -3.59 earnings per share for the current year.

Insider Transactions at UroGen Pharma

In related news, insider Mark Schoenberg sold 12,000 shares of the stock in a transaction that occurred on Monday, March 18th. The shares were sold at an average price of $14.05, for a total value of $168,600.00. Following the transaction, the insider now directly owns 139,437 shares in the company, valued at $1,959,089.85. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other UroGen Pharma news, insider Mark Schoenberg sold 12,000 shares of the company’s stock in a transaction that occurred on Monday, March 18th. The shares were sold at an average price of $14.05, for a total value of $168,600.00. Following the completion of the sale, the insider now owns 139,437 shares of the company’s stock, valued at $1,959,089.85. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, General Counsel Jason Drew Smith sold 4,993 shares of the company’s stock in a transaction that occurred on Wednesday, January 31st. The shares were sold at an average price of $15.74, for a total transaction of $78,589.82. Following the completion of the sale, the general counsel now directly owns 18,824 shares of the company’s stock, valued at approximately $296,289.76. The disclosure for this sale can be found here. Over the last three months, insiders have sold 20,782 shares of company stock worth $306,829. Corporate insiders own 11.13% of the company’s stock.

Institutional Investors Weigh In On UroGen Pharma

Several large investors have recently bought and sold shares of the company. RTW Investments LP increased its stake in UroGen Pharma by 101.4% in the fourth quarter. RTW Investments LP now owns 1,726,808 shares of the company’s stock valued at $25,902,000 after purchasing an additional 869,344 shares in the last quarter. RA Capital Management L.P. bought a new stake in shares of UroGen Pharma during the third quarter worth $20,787,000. Stonepine Capital Management LLC boosted its holdings in UroGen Pharma by 16.1% during the fourth quarter. Stonepine Capital Management LLC now owns 1,304,947 shares of the company’s stock worth $11,575,000 after purchasing an additional 180,727 shares during the last quarter. BlackRock Inc. boosted its holdings in UroGen Pharma by 285.9% during the second quarter. BlackRock Inc. now owns 1,097,916 shares of the company’s stock worth $11,363,000 after purchasing an additional 813,377 shares during the last quarter. Finally, Millennium Management LLC boosted its holdings in UroGen Pharma by 292.8% during the second quarter. Millennium Management LLC now owns 616,245 shares of the company’s stock worth $5,047,000 after purchasing an additional 459,341 shares during the last quarter. Institutional investors own 91.29% of the company’s stock.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.